The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
In a short-term perspective, the company has interesting fundamentals.
Carl Zeiss Meditec AG accounts for 4.99 % of our European Portfolio. A trade is currently open since 05/03/2019 with a purchase price of € 86.90. Discover the other 19 stocks of the European portfolio managed by the MarketScreener portfolio management team.
Thanks to a sound financial situation, the firm has significant leeway for investment.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The group usually releases upbeat results with huge surprise rates.
Sales forecast by analysts have been recently revised upwards.
For several months, analysts have been revising their EPS estimates roughly upwards.
The stock is in a well-established, long-term rising trend above the technical support level at 84.95 EUR
The company's "enterprise value to sales" ratio is among the highest in the world.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 53.45 times its estimated earnings per share for the ongoing year.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Sector Advanced Medical Equipment & Technology - NEC